PMID- 20642247
OWN - NLM
STAT- MEDLINE
DCOM- 20100810
LR  - 20191111
IS  - 1551-7489 (Print)
IS  - 1551-7489 (Linking)
VI  - 6
IP  - 3
DP  - 2010 May-Jun
TI  - Long-term tolerability and effectiveness of oxymorphone extended release in 
      patients with cancer.
PG  - 181-91
AB  - OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of 
      oxymorphone extended release (ER) in patients with cancer-related pain. DESIGN: 
      Post hoc analysis of two-1-year open-label extension studies. SETTING: Multiple 
      US cancer treatment facilities. PATIENTS: Patients with cancer pain who had 
      participated in two short-term crossover comparator trials of oxymorphone ER: one 
      open-label and one double-blind randomized. INTERVENTIONS: Patients who had been 
      taking oxymorphone ER continued the dose established in the previous study. 
      Patients who had been taking a comparator opioid were switched to an 
      equianalgesic dose of oxymorphone ER. All patients underwent individualized 
      oxymorphone ER dose titration to optimize effectiveness and tolerability. 
      ASSESSMENTS: Current, average, worst, and least pain scores were normalized to a 
      100-point scale. Patients rated treatment on a five-point global assessment of 
      study medication (Poor = 1 to Excellent = 5). All adverse events (AEs) were 
      recorded. RESULTS: Of the 80 patients who entered the extension trials, 26 
      completed 52 weeks, 7 discontinued owing to loss of effectiveness, and 20 
      discontinued owing to AEs, most of which were unrelated to study drug. No 
      significant increase in mean (standard deviation [SDD average pain intensity was 
      observed from baseline (30.5 [19.6], 100-point scale) to final visit (35.9 
      [21.1], p = 0.37). The most common AEs were concomitant disease progression (28.8 
      percent, n=23), nausea (22.5 percent, n=18), dyspnea (16.3 percent, n=13), 
      fatigue (16.3 percent, n=13), and edema of the lower limb (15 percent, n=12). 
      CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was 
      generally well tolerated and provided stable long-term pain control.
FAU - Slatkin, Neal E
AU  - Slatkin NE
AD  - Department of Supportive Care, Pain & Palliative Medicine, City of Hope Medical 
      Group (California Cancer Specialists Medical Group), Pasadena, California, USA.
FAU - Rhiner, Michelle I
AU  - Rhiner MI
FAU - Gould, Errol M
AU  - Gould EM
FAU - Ma, Tina
AU  - Ma T
FAU - Ahdieh, Harry
AU  - Ahdieh H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Opioid Manag
JT  - Journal of opioid management
JID - 101234523
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Delayed-Action Preparations)
RN  - 9VXA968E0C (Oxymorphone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Analgesics, Opioid/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*physiopathology
MH  - Oxymorphone/administration & dosage/adverse effects/*therapeutic use
MH  - Pain, Intractable/*drug therapy
EDAT- 2010/07/21 06:00
MHDA- 2010/08/11 06:00
CRDT- 2010/07/21 06:00
PHST- 2010/07/21 06:00 [entrez]
PHST- 2010/07/21 06:00 [pubmed]
PHST- 2010/08/11 06:00 [medline]
AID - 10.5055/jom.2010.0016 [doi]
PST - ppublish
SO  - J Opioid Manag. 2010 May-Jun;6(3):181-91. doi: 10.5055/jom.2010.0016.